Antidepresan Kullanımı Huzursuz Bacak Sendromu Riskini Arttırıyor mu?

Abstract

Gsm: +90 532 632 41 33 E-pos ta: emremb@yahoo.com Ge liş ta ri hi/Re cei ved: 27.06.2011 Ka bul ta ri hi/Ac cep ted: 22.08.2011 © Nö rop si ki yat ri Ar şi vi Der gi si, Ga le nos Ya yı ne vi ta ra f›n dan ba s›l m›fl t›r. / © Arc hi ves of Neu ropsy chi atry, pub lis hed by Ga le nos Pub lis hing. ABS TRACTObjective: Restless Legs Syndrome (RLS) is often associated with the use of antidepressants. However there is limited number of research about this association. The aim of this study was to investigate the relationship between antidepressant (AD) use and Restless Legs Syndrome (RLS). Methods: 247 patients diagnosed with depression and anxiety disorders were included in this study. A semi-structured data form was applied to all participants to assess socio-demographic and clinical characteristics. In this form, main four criteria proposed by International Study Group for RLS were used to determine RLS. For differential diagnosis of RLS, researchers interviewed patients who responded positively to all of the four questions. Results: Among patients who are included in the study, 41 (17.3%) patients were diagnosed with RLS. In 35 of these patients (85.4% of the whole group), RLS is found to appear or increase with the use of antidepressants. In patients with the diagnosis of RLS, selective serotonin reuptake inhibitors (SSRI) were the mostly used antidepressant group. Mostly used antidepressants were essitalopram, trazodone and venlafaxine. The evaluation made in the whole group and separately in the male and female groups revealed that use of SSRIs, selective noradrenaline reuptake inhibitors (SNRI) or tricyclic antidepressants (TCA) was not related with RLS. In females, use of trazodone and combined therapy of trazodone and ADs increased the risk of RLS significantly. Discussion: The results of our study suggested that occurrence of RLS is especially common in patients using SSRIs, but use of SSRIs, SNRIs or TCAs were not significant risk factors for the development of RLS. In female patients, use of traodone increased RLS risk, and increased risk was found to be especially associated with combination treatment. In the combination treatment, alterations in the drug metabolism may contribute to the development of RLS with ADs. Also the effect of trazodone and its active metabolite m-chloropiperazine on serotonin may be associated with the increased risk of RLS. An increase in RLS risk should be considered in occasions when clinicians prefer trazodone in combination treatment such as insomnia. (Arc hi ves of Neu ropsy chi atry 2012; 49: 212-217) Conflict of interest:The authors reported no conflict of interest related to this article. ÖZETAmaç: Huzursuz Bacak Sendromu (HBS) antidepresan (AD) kullanımıyla sıklıkla ilişkilendirilmektedir. Ancak bu ilişkiyi inceleyen araştırma sayısı sınırlıdır. Bu çalışmanın amacı AD kullanımı ile HBS arasındaki ilişkiyi araştırmaktır. Yön tem: Ça l›fl ma ya dep res yon ve ank si ye te bo zuk luk la r› ta n› s› alan 247 has ta al›nd›. Ka t› l›m c› la ra sos yo de mog ra fik ve kli n...